Navigation Links
VEGF may not be relevant biomarker for advanced prostate cancer
Date:4/29/2013

PHILADELPHIAThe well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.

VEGF, or vascular endothelial growth factor, induces blood vessel growth, a process known as angiogenesis, which is a key element in solid tumor growth and metastasis. It is overexpressed, along with its receptors, in various cancers, including breast, renal cell carcinoma and gliomas, and has been shown to help predict response to certain drugs.

However, conflicting data in the literature has left the role of VEGF in prostate cancer as a useful biomarker unclear and controversial.

Here, in one of the largest studies of VEGF expression in prostate cancer, senior author Adam P. Dicker, MD, PhD, Chair of the Department of Radiation Oncology at Jefferson, and colleagues retrospectively analyzed data from two groups of men with locally advanced prostate cancer: those who had only radiation therapy and those who had short-term neoadjuvant and concurrent androgen deprivation therapy and radiation therapy.

Data was collected using pathologic material of over 100 men from the Radiation Therapy Oncology Group 8610 phase III randomized control trial to explore VEGF's potential as a biomarker, one that could be used to improve the treatment of prostate cancer patients through better targeted therapies.

Based on the results, however, researchers posit that the VEGF protein may not be a relevant biomarker for this patient group. They found no statistically significant difference in pre-treatment characteristics among men with varying VEGF levels and no correlation between VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or biochemical failure.

What's more, there was no difference between the two treatment arms, those who had androgen therapy and radiation therapy and those who just had radiation. The median follow up time was for all surviving patients was 12.2 years.

"VEGF in this disease does not have a driver role," said Dr. Dicker. "The clinical trials using VEGF inhibitors did not have clinical benefit, so this study confirms that this is not a path forward to tacking this disease."

The results are not definitive statements about VEGF, the authors explain, but reporting on this well-characterized population with long-term follow is a significant contribution to the literature.

"This study is among the larger studies of VEGF expression in prostate cancer, and we urge the research community to avoid the misrepresentation of the literature with a lack of publication of even well-designed large negative studies, a publication bias against negative trials, as the current literature in this area appears to be predominated by only small exploratory positive trials, with a lack of subsequent confirmation with larger, longer prospectively designed trials," the authors write.

Other institutions included Prince Edward Island Cancer Treatment Centre, University of Pennsylvania, Abington Hospital, University of California, San Francisco, Melre M. Mahr Cancer Center, University of Miami, and the Intermountain Medical Center.


'/>"/>

Contact: Danielle Servetnick
danielle.servetnick@jefferson.edu
215-955-2238
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Smoking affects allergy-relevant stem cells
2. CNIO researchers describe new functions of cohesin relevant for human disease
3. Possible predictive biomarker for patients who may respond to autophagy inhibitors
4. Office workers carry biomarker of potentially harmful flame retardant, study finds
5. Trio of biomarkers may help identify kidney cancer in early stages
6. Biomarkers may help predict progression of Barretts esophagus to esophageal adenocarcinoma
7. Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors
8. CT texture analysis of tumors may be a valuable biomarker in localized esophageal cancer
9. DAI provides potential imaging biomarker to indicate brain tumor response to RT
10. Mayo Clinic-led study identifies biomarkers for early risk assessment of acute kidney injury
11. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident ... Main Residency Match® (“the Match”), the system through which U.S. and international medical ... record-high 30,750 positions were placed in the 2016 Match, and 29,572 were filled ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist ... patients can visit Dr. Assili to receive any dental extraction treatment for $40 off ... expires June 30, 2016. With the lower price, patients can more easily afford extractions ...
(Date:5/2/2016)... Las Vegas, NV (PRWEB) , ... May 02, ... ... with Specialty Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award ... be determined based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... medications, including anxiolytics, painkillers, antidepressants and cholesterol-lowering drugs, may cause cognitive impairment ... Center —a leading Florida-based drug treatment facility—advises patients to research the potential ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... urgent care facilities designed to automate and improve the rapid diagnosis, triage and ... is demonstrating their platform, application, and mobile experience for the first time at ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
Breaking Medicine Technology: